Vizgen closed a $48 million financing led by Arch Venture Partners, M Ventures and Northpond Ventures to accelerate commercial growth, scale operations and push toward profitability. The company will invest in consumables, software, and faster turnaround for custom content products tied to its MERFISH spatial transcriptomics platform. Vizgen highlighted recent MERFISH 2.0 chemistry and expanded proteomics offerings (InSituPlex and StarVue) as positioning advantages in the spatial biology race; management also called out an imminent competitive launch from Illumina for spatial products in 1H. The funding will support global field teams and R&D updates the company plans to share at the AGBT meeting. Investors view the capital as enabling Vizgen to commercialize next‑generation spatial multiomics tools while defending market share as larger genomics incumbents expand into spatial assays.